Phase I clinical trial with alpha 1,3,5-triglycidyl-s-triazinetrione (NSC-296934)

1,3,5 -Triglycidyl- s -triazinetrione is a triepoxide derivative with attractive antitumor properties in mice. In this phase I trial, the drug was given as an i.v. infusion over 30 + min repeated every 2–3 weeks. The trial was initiated at a starting dose of 33 mg/m 2 and doses were escalated up to 2,000 mg/m 2 . Local thrombophlebitis was dose-limiting and apparently dose-related. Other toxic effects were mild to moderate and consisted of nausea, vomiting, leukopenia and hair loss. More favorable formulations or schedules of administration are needed before testing this new agent in phase II trials.